Viagra Helps Mountaineers Perform at Altitude by Van Peursem, Philip
Pacific University
CommonKnowledge
School of Physician Assistant Studies Theses, Dissertations and Capstone Projects
12-11-2012
Viagra Helps Mountaineers Perform at Altitude
Philip Van Peursem
Follow this and additional works at: http://commons.pacificu.edu/pa
Part of the Medicine and Health Sciences Commons
This Capstone Project is brought to you for free and open access by the Theses, Dissertations and Capstone Projects at CommonKnowledge. It has
been accepted for inclusion in School of Physician Assistant Studies by an authorized administrator of CommonKnowledge. For more information,
please contact CommonKnowledge@pacificu.edu.
Recommended Citation
Van Peursem, Philip, "Viagra Helps Mountaineers Perform at Altitude" (2012). School of Physician Assistant Studies. Paper 422.
Viagra Helps Mountaineers Perform at Altitude
Abstract
Background: Many people work and play at higher altitudes where hypoxia can cause altitude sickness and
hamper one’s ability to carry out physical tasks. Nifedipine is currently the adjunct drug of choice for altitude
sickness, but it carries the risk for hypotension. There is evidence that sildenafil can be used to prevent high
altitude pulmonary edema (HAPE), and given its excellent safety profile, may prove to be a viable alternative.
What is the usefulness of sildenafil in the prevention of HAPE and the improvement of aerobic capacity in
young healthy adults at high altitudes?
Methods: An exhaustive search of available literature was conducted using the search terms: [sildenafil or
PDE or phosphodiesterase] and [altitude or altitude sickness] and [hypoxia or anoxia] and pulmonary
hypertension. Only studies that also analyzed some component of athletic performance were considered.
Results: Five studies met the final inclusion criteria investigating the effects of sildenafil during hypoxic
exercise. The Lalande et al study found that sildenafil caused a blunted respiratory drive with no change in
peripheral oxygen saturation (SpO2) and a decrease in right ventricle systolic pressure (RVSP). The Hsu et al
study found that sildenafil increased cardiac output (Q), SpO2, and improved cycling performance as well.
The Ghofrani study found that sildenafil improved Q and cycling power while decreasing pulmonary artery
pressure (PAP) in both acute and chronic hypoxia. The Ricart study found that sildenafil reduced PAP and
slightly improved SpO2. The Richalet study found improved SpO2, PAP, Q, and maximum oxygen
consumption (VO2 max).
Conclusion: The data from these 5 studies suggests that sildenafil can be used to prevent pulmonary
hypertension and therefore reduce the risk for HAPE during hypoxic exercise. It also suggests that sildenafil
can prevent hypoxia-induced decreases in exercise tolerance and aerobic capacity. There is no data comparing
the efficacy of sildenafil and nifedipine and clinical experience with sildenafil for this purpose is limited. At
this time sildenafil should only be considered an alternative to nifedipine in the prevention of HAPE and
aerobic decline.
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ABSTRACT 
 
Background:  Many people work and play at higher altitudes where hypoxia can cause altitude 
sickness and hamper one’s ability to carry out physical tasks.  Nifedipine is currently the adjunct 
drug of choice for altitude sickness, but it carries the risk for hypotension.  There is evidence that 
sildenafil can be used to prevent high altitude pulmonary edema (HAPE), and given its excellent 
safety profile, may prove to be a viable alternative.  What is the usefulness of sildenafil in the 
prevention of HAPE and the improvement of aerobic capacity in young healthy adults at high 
altitudes? 
 
Methods:  An exhaustive search of available literature was conducted using the search terms: 
[sildenafil or PDE or phosphodiesterase] and [altitude or altitude sickness] and [hypoxia or 
anoxia] and pulmonary hypertension. Only studies that also analyzed some component of athletic 
performance were considered. 
 
Results:  Five studies met the final inclusion criteria investigating the effects of sildenafil during 
hypoxic exercise.  The Lalande et al9 study found that sildenafil caused a blunted respiratory 
drive with no change in peripheral oxygen saturation (SpO2) and a decrease in right ventricle 
systolic pressure (RVSP).  The Hsu et al10 study found that sildenafil increased cardiac output 
(Q), SpO2, and improved cycling performance as well.  The Ghofrani et al11 study found that 
sildenafil improved Q and cycling power while decreasing pulmonary artery pressure (PAP) in 
both acute and chronic hypoxia.  The Ricart et al12 study found that sildenafil reduced PAP and 
slightly improved SpO2.  The Richalet et al13 study found improved SpO2, PAP, Q, and 
maximum oxygen consumption (VO2 max). 
 
Conclusion:  The data from these 5 studies suggests that sildenafil can be used to prevent 
pulmonary hypertension and therefore reduce the risk for HAPE during hypoxic exercise.  It also 
suggests that sildenafil can prevent hypoxia-induced decreases in exercise tolerance and aerobic 
capacity.  There is no data comparing the efficacy of sildenafil and nifedipine and clinical 
experience with sildenafil for this purpose is limited.  At this time sildenafil should only be 
considered an alternative to nifedipine in the prevention of HAPE and aerobic decline. 
 
Keywords: sildenafil, pulmonary hypertension, hypoxia, exercise, high altitude, HAPE, AMS 
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Viagra Helps Mountaineers Perform 
BACKGROUND 
 Acute hypoxia presents certain physiological challenges to people who work or play in 
high altitude environments.  Decreased oxygen saturation limits aerobic capacity and exercise 
tolerance.  It can also lead to altitude sickness, a broad spectrum of symptoms ranging from a 
mild headache and fatigue in acute mountain sickness (AMS), to severe high altitude cerebral 
edema (HACE) which is potentially fatal.  The likelihood and severity of symptoms in altitude 
sickness is largely influenced by genetic predisposition.  Even well-trained athletes who 
routinely spend time at altitude can be affected if they are susceptible and not adequately 
acclimatized. 
 High altitude pulmonary edema (HAPE) is a potentially fatal form of altitude sickness 
which has a mortality rate of 44%, if left untreated.1  Patients initially present with a dry cough, 
fatigue, and exertional dyspnea, but may progress to severe shortness of breath and dyspnea at 
rest with worsening cough, audible rales, and pink frothy sputum in extreme cases.  Severe 
hypoxemia, disproportionate to the current altitude, is another typical finding, and, while the 
diagnosis is typically a clinical one, chest radiography may show patchy peripheral infiltrates. 
 A number of contributory mechanisms have been identified, but the primary mechanism 
seems to be exaggerated pulmonary vasoconstriction, in response to acute hypoxia.  During 
situations of isolated regional hypoxia, this mechanism helps maintain an optimal ventilation-
perfusion ratio, by shunting blood away from areas of the lung which are receiving inadequate 
ventilation.  However, in instances of global hypoxia, this otherwise beneficial mechanism is 
problematic because it results in severe pulmonary artery hypertension in excess of 26-31 
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mmHg.2  The vasoconstrictor response is exaggerated and non-uniform, meaning that some 
capillary beds are exposed to excessively high pressures resulting in endothelial damage, 
increased capillary permeability, and fluid accumulation within the alveolar space.2  The 
resulting edema impairs oxygen diffusion and exacerbates pre-existing hypoxemia, causing a 
further decline in aerobic capacity and athletic performance. 
 According to the 2010 Wilderness Medical Society Consensus Guidelines for the 
Prevention and Treatment of Acute Altitude Illness,3 the most effective method in the prevention 
of HAPE, and altitude sickness in general, is a gradual ascent of <500 m per day at altitudes 
above 2500 m.  In individuals who are prone to altitude sickness, nifedipine can be used as a 
prophylactic adjunct.  There is also evidence supporting the use of phosphodiesterase-5 (PDE-5) 
inhibitors such as Viagra (sildenafil) in the prevention of HAPE, which may prove to be an 
attractive option to those in whom nifedipine is not well-tolerated. 
 Pulmonary vasoconstriction has been associated with decreased levels of nitric oxide and 
cGMP in the lungs.4  PDE-5 decreases levels of cGMP, therefore PDE-5 inhibitors, such as 
sildenafil, increase levels of cGMP and reduce pulmonary vascular pressure.5,6,7  Does this effect 
extend to those engaged in strenuous physical activity, and is it associated with an improvement 
in peripheral oxygenation and exercise tolerance at altitude? 
METHODS 
 An exhaustive search of available literature was conducted in Medline (OVID and 
Pubmed), CINAHL and EBMR Multifile using the search terms: [sildenafil or PDE or 
phosphodiesterase] and [altitude or altitude sickness] and [hypoxia or anoxia] and pulmonary 
hypertension.  The search was narrowed to include only RCTs involving healthy (no pre-existing 
pulmonary or cardiovascular disease) human subjects and studies that also analyzed some 
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component of hypoxic athletic performance.  Studies that used conditions of simulated high 
altitude (hypobaric chamber, altitude tent, face mask) were also included.  The bibliographies of 
the remaining articles were then searched for additional relevant studies, and only those with 
primary data evaluating the efficacy of sildenafil in preventing pulmonary hypertension and 
hypoxemia in healthy patients under hypoxic conditions were included.  A search on the 
National Institute of Health clinical trials site revealed no currently registered trials, in any phase, 
relating to this topic which had not already been identified in the literature search.  Finally, 
relevant articles were assessed for quality using the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE) criteria.8 
RESULTS 
 The initial search yielded 37 articles which, after screening for appropriate design and 
relevancy and excluding those which did not meet inclusion criteria, left a total of 5 
articles9,10,11,12,13 for review.  All of the articles were RCTs and four of them9,10,11,12 were 
crossover studies. 
 
Lalande et al 
 This randomized, double-blind, placebo-controlled crossover study9 published in 2006 
directly compared the effects of sildenafil and acetazolamide on breathing efficiency and 
ventilatory control during steady-state submaximal hypoxic exercise.  For the purposes of this 
review, only the effects of sildenafil compared to placebo were considered.  The study analyzed 
numerous respiratory parameters including respiratory rate (RR), inhalation time (Ti), exhalation 
time (Te), tidal volume (Vt), minute ventilation (Vm), oxygen uptake (VO2) and breathing 
efficiency, as well as cardiovascular parameters including arterial oxygen saturation (SaO2), 
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heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial 
pressure (MAP), and right ventricular systolic pressure (RVSP). The study also assessed 
participants for symptoms of acute mountain sickness (AMS).9 
 Methods— The study recruited 15 young (34.8 ± 2.4 years), aerobically fit (VO2 max of 
39.3 ± 2.6 ml/kg/min) individuals, 8 men and 7 women, who had no cardiovascular or 
pulmonary disease, and did not have a history of migraines or severe headaches.  Participants 
were excluded if they were currently taking alpha blockers or nitrates.  Participants underwent 
exercise testing on a cycle ergometer to determine their baseline VO2 max while breathing room 
air at sea-level.  Workload was increased incrementally every 2 minutes until exhaustion while 
respiratory data was collected and analyzed every 5 seconds.9 
 For the hypoxic phase of the study, participants spent 18 hours in an altitude tent 
breathing air with an oxygen concentration (FiO2) of 12.5% (ppO2 95 mmHg) simulating an 
altitude of 4300 m (~14 000 ft) above sea level, followed by 10 minutes of hypoxic exercise  at 
40% of their sea-level VO2 max.  Participants underwent three of these 18-hour hypoxia sessions, 
each separated by at least 24 hours to prevent crossover effects.  For the 26 hours prior to each 
session, participants were randomly given 40 mg oral sildenafil, 125 mg oral acetazolamide or 
placebo on 4-times-daily basis to allow for adequate uptake of the drug.  Randomization methods 
were unspecified.  Respiratory parameters were measured using a breath-by-breath analysis 
system.  Sa02 and HR were monitored continuously with a finger pulse oximeter, and blood 
pressure was taken manually every 2 minutes.  The right ventricle systolic pressure (RVSP) was 
estimated using Doppler echocardiography before, immediately after, and 10 minutes after the 
completion of exercise testing.  The Lake Louise Score (LLS)14 was used to subjectively assess 
symptoms of AMS.9 
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Results— There was no difference in LLS between interventions during hypoxia.  When 
compared to placebo, sildenafil tended to decrease Vm (P = 0.12) and RR (P = 0.052) while 
increasing Vt,Ti and Te; whereas, breathing efficiency, VO2, and SaO2 did not change.  It was 
also observed that sildenafil increased HR and reduced SBP and MAP, and tended to decrease 
RVSP before, and 10 minutes after, exercise (P = 0.09, 0.04) but there was no change 
immediately after exercise.  Overall, the results showed that sildenafil reduced respiratory drive 
without affecting oxygenation and also caused a decrease in RVSP.  No significant adverse 
reactions to sildenafil were reported, and there was no loss to follow-up in this study.9 
Conclusions— The authors concluded that, although they did not directly measure the PAP, 
it is a possible reason for the decreased respiratory response to hypoxic exercise that tended to 
occur in subjects taking sildenafil.  This was supported by an observed decrease in RVSP of 11-
23% which, according to the authors, may have been underestimated by measuring the RVSP at 
rest rather than during exercise, when pressure would be higher, making the effect of sildenafil 
more pronounced.  The authors also found that, contrary to a number of studies,10,11,12,13 
sildenafil did not improve SaO2 during hypoxic exercise.  They attribute this discordant result to 
a lower exercise intensity, as well to the milder (12.5% vs. 10% FiO2) and more acute (<24 hrs) 
hypoxic conditions used in this particular study.  They believed that the conditions of this study 
were not severe enough to cause the degree of pulmonary vasoconstriction necessary to elicit 
significant effects from sildenafil.  From these findings, the authors concluded that the effects of 
sildenafil may only be appreciated after several days of moderate hypoxia, more severe acute 
hypoxia, or maximal exercise intensity under hypoxic conditions.9 
The authors acknowledge that this study was limited by the use of an altitude tent which does 
not reproduce the hypobaric conditions of high altitude, and therefore, may not truly replicate the 
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physiologic response of acclimatization.  Also, the small sample size of the study limited the 
ability to detect small changes which may have been detected in a larger study.9 
 
Hsu et al 
This randomized, double-blind, placebo-controlled, crossover study10 published in 2006 
investigated the effects of sildenafil on cardiac output and athletic performance under hypoxic 
and room air conditions.  This study analyzed cardiac output (Q), stroke volume (SV), heart rate 
(HR), systolic blood pressure (SBP), arterial oxygen saturation (SaO2), rating of perceived 
exertion, VO2 max, time trial (TT) finish time, and cycling wattage (W).  Measurements were 
taken for submaximal and high intensity exercises both at sea-level conditions and in acute 
hypoxia.10 
Methods— The study recruited 10 young (age 31 ± 4 yrs) healthy male volunteers who 
were all well-trained cyclists and triathletes (13.5 ± 5.5% body fat, VO2 max of 59.7 ± 9.5 
ml/kg/min).  None had any health conditions which would interfere with physical activity, and 
none had any reported history of HAPE.  Baseline aerobic capacity (defined by VO2 max) and 
max power output (defined by Wmax) were assessed using a cycle ergometer.  Workload was 
incrementally increased until exhaustion while respiratory gases were continuously analyzed 
using a non-rebreathing valve apparatus.  This test was repeated no less than 3 days later to 
ensure consistent results and establish baseline values.10 
Three sea-level testing sessions were conducted; each consisting of cycling for 1 hour at 
55% of each participant’s predetermined sea-level Wmax, followed by a 10-km maximum effort 
time trail (TT).  One hour prior to each session, participants were given placebo or sildenafil, 
either 50 mg or 100 mg.  Interventions were given in a randomly counterbalanced order so that 
by the third session each participant had received each intervention.  Each session was separated 
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by at least three days to eliminate any possible crossover effects.  Randomization methods were 
not specified.10 
For the simulated high-altitude portion of the trial, participants breathed air with 12.8% 
FiO2  (ppO2 97 mmHg) during exercise, and for 1 hour prior.  Similar to the sea-level testing, 
participants completed a baseline exercise session followed by 3 experimental sessions, each 
separated by at least 3 days, in which the interventions were given.  The experimental sessions 
involved 30 minutes of exercise at 55% of their hypoxic Wmax followed by a 6-km TT.  No 
explanation was given as to why the hypoxic exercise session was shorter in duration than the 
sea-level one.  Also, VO2 was not measured during the hypoxic sessions.10 
Results— Compared to sea level, Wmax, SaO2, Q, and HR all decreased significantly 
during acute hypoxia.10 
During submaximal exercise in acute hypoxia, sildenafil produced significant increases in 
Q as well as SV and SaO2, while significantly decreasing SBP compared to placebo.  During the 
hypoxic TT, sildenafil significantly improved finish time while increasing average power output, 
Q, and SaO2.  This supports the idea that sildenafil does in fact improve oxygenation, 
cardiovascular response and performance during acute hypoxia.  However, the authors found no 
difference between 50 mg and 100 mg of sildenafil for any data point.10 
In a retrospective analysis, the authors discovered two subsets within their data: one 
group appeared to have a much better response to sildenafil and another whose response was 
comparatively small.  Although there was an overall significant improvement in TT finish time  
(-15%) with sildenafil, the responders improved significantly more than non-responders (-39% 
vs. -1%) and also had significantly better Q and SaO2, both at rest and during exercise.  
Responders, however, also had a significantly larger decrease in SV between sea level and acute 
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hypoxia, than the non-responders.  Some participants experienced common side effects of 
sildenafil including headache, facial flushing, and blue vision.  One participant experienced 
headaches which were severe enough to prevent him from continuing with the study.  His data 
set was excluded from the analysis.10 
Conclusions— The authors concluded from this study that sildenafil significantly 
reduced the effects of acute hypoxia on exercise performance, both for high intensity and for 
lower intensity exercise.  This more accurately reflects the type of physical activity experienced 
by people who work and play in higher altitudes where long stretches of continuous low-
intensity activity is occasionally punctuated by short bursts of high-intensity activity.  Also, the 
simulated altitude used here was lower than that used in other studies (3874 vs. 5000+ m) which 
the authors believe to be more relevant to athletic competition and recreational mountaineering.10 
 Sildenafil responders showed greater improvement in Q and TT time than the non-
responders did.  This same group, however, which showed greater improvement with sildenafil, 
also showed greater decrement with hypoxia, suggesting that those who respond to sildenafil 
may be more susceptible to the effects of hypoxia and HAPE in the first place.  The authors also 
noted that those individuals who suffered the greatest drop in Q during hypoxia were also the 
ones who had the highest Q, VO2 max and the lowest TT time at sea level.  This finding suggests 
that those individuals who generally have better cardiac output at sea-level quickly lose that 
advantage in acute hypoxia, but they also seem to gain the most benefit from sildenafil which 
may negate these detrimental effects.10 
The authors surmised that sildenafil’s effects are likely due to a reduction in the hypoxia-
induced pulmonary vasoconstrictor response, decreasing pulmonary artery pressure (PAP) and 
improving the ventilation-perfusion ratio (V:Q).  However, the authors do not support the use of 
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sildenafil as a high-altitude performance-enhancing drug, since it has been shown to increase Q 
which can increase PAP and, potentially, the risk for HAPE.10 
One of the major limitations of this study is the fact that PAP was never directly 
measured; instead Q (SV x HR) was used as a surrogate endpoint.  The authors chose to use 
these surrogates because measuring PAP by direct catheterization is far too invasive, and 
estimation of PAP by echocardiography is difficult and subject to operator interpretation.  
Therefore they used Q as a more practical substitute for PAP.  Another limitation, which the 
authors address, is the use of a relatively new and unproven device, the Physioflow, which is 
based on updated impedance cardiography.  Its use has been verified in exercise by a few studies, 
but never at altitude, so its reliability remains uncertain.10 
 
Ghofrani et al 
 This randomized, double-blind, placebo-controlled crossover study11 published in 2004, 
investigated the effects of sildenafil on pulmonary hemodynamics, gas exchange and exercise 
tolerance during acute and chronic hypoxia.  The study examined heart rate (HR), systolic blood 
pressure (SBP), pulmonary artery pressure (PAP), cardiac output (Q), peripheral oxygen 
saturation (SpO2), and exercise tolerance defined as Wmax.  Measurements were compared 
between rest and exercise at low altitude, sildenafil against placebo during rest and exercise 
under acute hypoxia, sildenafil against. placebo during rest and exercise under chronic hypoxia.11 
Methods— This study used 14 young (33-44 years old) healthy volunteers who all had 
experience at altitude either as trekkers or mountaineers and did not have a history of HAPE or 
any other pertinent health history.  All participants received a medical screening and baseline 
testing prior to the experimental phase.  They measured PAP by portable Doppler 
echocardiography and Q was measured by using a gas-rebreathing device.  Exercise capacity, as 
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defined by maximum wattage output (Wmax), was measured on a cycle ergometer by 
incrementally increasing workload until exhaustion was reached.  Each exercise session was 
performed in this manner.11 
The low-altitude phase of the study took place in Giessen, Germany at an altitude of 171 
m (561 ft) above sea level.  Measurements were taken while breathing room air at rest, and again 
during exercise.  After a minimum of 6 hours of rest, participants began the acute hypoxia phase 
of the study.  They breathed a hypoxic mixture of 10% FiO2 (ppO2 70 mmHg), simulating an 
altitude of 6431 m (1414 ft)  above sea level,15 for 2 hours prior to exercise.  At 1 hour prior to 
exercise participants were randomly given an intervention, either placebo or 50 mg of oral 
sildenafil.  Interventions were package identically and randomization by an outside third party.  
Just prior to exercise, measurements were taken while the participants were at rest and again 
during exercise.  Another exercise session was conducted the following day in the same manner 
with participants receiving either placebo or sildenafil per the crossover design.  Crossover effect 
between the two interventions was avoided by separating the exercise sessions by at least 24 
hours.11 
For the high altitude phase of the study, all participants travelled to Kathmandu (1330 m) 
and, from there, gradually ascended to Mt. Everest base camp (5245 m) over a period of 8 days, 
followed by an additional 6 days of acclimatization at base camp.  Exercise testing was 
conducted over 2 days in the same manner as in the low-altitude phase, with measurements being 
taken at rest and during exercise.  Sildenafil and placebo were again administered in a crossover 
pattern prior to both exercise sessions.11 
[16] 
 
Results—  Hypoxia caused significant changes from baseline in certain measurements.  
It decreased SpO2 for both rest and exercise, increased systolic PAP for both rest and exercise, 
and decreased Q for exercise but not for rest.  It also decreased Wmax.11 
In acute hypoxia, sildenafil did not significantly affect Q during rest, but there was a 
significant increase during exercise, while systolic PAP was significantly lower at rest and 
during exercise.  With sildenafil, SpO2 was significantly higher during exercise but not while 
resting.  Sildenafil had no significant effects on HR or SBP, neither at rest nor during exercise, 
but it did significantly improve Wmax.  No significant adverse effects were noted with sildenafil 
during this phase.11 
After several days of exposure to hypoxia at the Everest base camp, the values for all 
measurements improved towards baseline compared to those taken during acute hypoxia as 
subjects began to acclimatize to the altitude.  Sildenafil significantly decreased systolic PAP both 
at rest and during exercise, and also significantly increased Wmax.  Sildenafil increased both HR 
and Q during exercise, but not at rest, and had no significant effect on SpO2.  During this phase, 
2 participants experienced severe headaches after taking sildenafil.  One could not continue with 
the exercise testing so his exercise data for both placebo and sildenafil were excluded.  The 
crossover design of this study prevented the data from being skewed by this exclusion.11 
Conclusions— The authors found that the administration of 50 mg oral sildenafil 
reduced hypoxia-induced pulmonary hypertension and improved cardiac output and exercise 
tolerance with little to no effect on HR or BP.  This suggests that sildenafil’s mechanism is 
primarily pulmonary rather than cardiac in nature.  Reduction of PAP and right ventricle 
afterload is the likely mechanism by which sildenafil improves cardiac output and pulmonary 
flow.11 
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Sildenafil improved peripheral oxygenation during exercise in acute hypoxia but not after 
acclimatization to prolonged hypoxia.  Considering that PAP was still lower with sildenafil even 
after acclimatization, this suggests that a reduction in PAP after acclimatization has occurred, 
does not produce any further improvement in oxygen saturation.  The implication is that 
sildenafil may be more effective when used to prevent symptoms during acute hypoxia, before 
acclimatization occurs.11 
The authors acknowledged some limitations of this study.  They did not examine the 
effects of sildenafil on exercise at normal oxygen levels.  They only studied individuals with no 
history of altitude sickness; they did not examine the effects on those who are prone to it.  Two 
of the participants suffered severe headaches after taking sildenafil.  This may have been a side 
effect of the drug, a migraine, or a symptom of acute mountain sickness.  It may have been some 
combination of these factors, but it is hard to tell since the symptoms are very similar.11 
 
 
Ricart et al 
 This randomized, double-blind, placebo-controlled crossover study12 published in 2005, 
investigated the effects of sildenafil on pulmonary artery pressure, oxygenation and 
cardiopulmonary functioning during acute hypoxia, both at rest and after submaximal exercise.  
The study examined heart rate (HR), respiratory rate (RR), peripheral oxygen saturation (SpO2), 
tidal volume (Vt), pulmonary artery pressure (PAP), and left ventricle ejection fraction (EF).  
Measurements were taken during normoxic rest, hypoxic rest, hypoxic exercise, and normoxic 
exercise.12 
 Methods— In this study, 17 young (33.1 ± 7.2 years) male volunteers participated.  All 
lived at sea level and none had been above 4000 m within the past year.   A hypobaric chamber 
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was used to simulate an altitude of 5000 m (16 400 ft) above sea level with a ppO2 of 85 mmHg.  
Each participant underwent two 90-minute chamber sessions separated by at least 24 hours to 
eliminate medication crossover effects.  At 15-20 minutes prior to each session, participants were 
randomly given either placebo or 100 mg oral sildenafil in a crossover manner.  Randomization 
was not described.  During each session, participants exercised for 5 minutes during hypoxia, 
and for another 5 minutes after returning to room air.  Exercise consisted of using a cycle 
ergometer at a fixed workload associated with 50% of each participant’s theoretical VO2 max.  
Physiologic measurements were taken while participants were resting in room air, after resting in 
hypoxia for 5 minutes, immediately after hypoxic exercise, and immediately after exercise in 
room air.  A finger pulse oximeter was used to measure SpO2 and HR.  Data used to calculate 
PAP and EF was obtained by a portable echocardiograph.  A spirometer was used to measure RR 
and Vt.12 
 Results—  Both hypoxia and exercise caused a significant increase in PAP and a 
significant decrease in SpO2, with the combination of the two conditions having an even greater 
effect.12 
Compared to placebo, when participants took sildenafil, PAP was significantly lower 
during hypoxia, both at rest and after exercise.  There was a small but significant increase in 
SpO2 after hypoxic exercise with sildenafil, but no effects under any other condition.  There were 
also small but significant increases in HR during normoxic rest and normoxic exercise, as well as 
hypoxic rest but no effect during hypoxic exercise.  Sildenafil had no significant effects on EF, 
RR or Vt under any condition.12 
 Headache and mild skin reddening were the only medication side effects reported, but, 
according to the authors, these were not sufficient to compromise the double-blinding.  
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Echocardiograph data was rejected in 3 individuals for some reason not specified by the authors.  
These 3 data sets were excluded from the study analysis.12 
 
Conclusions— The authors concluded that sildenafil decreases pulmonary hypertension 
during acute hypobaric hypoxia but has no effect during normoxic conditions.  This implies a 
mechanism that inhibits the hypoxia-induced pulmonary vasoconstrictor response which would 
alter the ventilation-perfusion ratio and improve oxygenation.  When participants took sildenafil 
during hypoxia, oxygenation was improved without affecting ventilatory parameters.  This 
further suggests that such an alteration did occur.  However, the question of whether or not 
sildenafil can prevent HAPE during hypoxic exercise still remains unclear due to the lack of an 
observed blunted ventilatory response or substantial improvement in oxygenation.12 
The authors acknowledged that even though the effect on PAP was statistically 
significant it still may have been underestimated due to methodological limitations of the study.  
Hypoxic rest measurements were taken only 5 minutes after reaching maximum hypoxia, which 
may not have been enough time for the pulmonary vasculature to fully react, and therefore 
resting hypoxic PAP may have been underestimated.  Also, there was an “insignificant” delay 
between the end of the exercise period and the start of the echocardiographic exam.  But this 
delay may still have been enough to allow for a drop in the PAP before it could be measured.12 
 
Richalet et al 
 This randomized, double-blind, placebo-controlled study13 published in 2005 set out to 
investigate the effects of sildenafil on pulmonary hemodynamics, oxygenation, exercise 
tolerance and symptoms of acute mountain sickness (AMS) in healthy subjects exposed to high 
altitude hypoxia over the course of several days.  The study measured pulmonary artery pressure 
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(PAP), pulmonary acceleration time (PAT), intra-thoracic fluid (ITF) index, heart rate (HR), 
systemic blood pressure (SBP), arterial oxygen saturation (SaO2), maximum oxygen  
consumption (VO2 max), cardiac output (Q), color vision (CV), and Lake Louise score (LLS) for 
acute mountain sickness (AMS), as well as blood levels of cGMP, sildenafil and hematocrit.13 
 Methods— This study used 12 young (29 ± 6 yrs), healthy males who were “moderately 
trained,” unacclimatized to altitude, and had no reported history of severe altitude sickness.  
Baseline measurements were taken for 3 days in Bobigny, France at an altitude of 60 m (197 ft) 
above sea level.  Doppler echocardiography was used to calculate pulmonary hemodynamics at 
rest while transthoracic impedencemetry was used both at rest and during exercise.  Exercise 
testing was conducted on a cycle ergometer with workload increasing incrementally until 
participants reached exhaustion.  After a day in Chamonix, participants were airlifted to the 
Observatoire Vallot at an altitude of 4350 m (14 270 ft) above sea level.  They remained there 
for 6 days while receiving either placebo (n=6) or 40 mg oral sildenafil (n=6) three times daily, 
before returning to sea level.  Randomization and cohort matching were not described.  In 
addition to the baseline session at sea level, participants underwent exercise testing on day 2 and 
day 6 of their stay at altitude, and again after returning to sea level.  The study lasted for a total 
of 12 days.13 
 Results— Neither BP, CV or LLS were affected by treatment.  At altitude, HR was 
significantly lower while SpO2 was significantly higher in the sildenafil group compared to 
placebo.  PAP increased in both groups at altitude, but after 1-2 days it dropped significantly 
lower in the sildenafil group and remained lower compared to placebo until participants returned 
to sea level.  In fact, by day 5-6 at altitude, there was no significant difference in PAP compared 
to sea level in the sildenafil group.  A similar response was seen with PAT.  It decreased with 
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altitude in both groups, but returned to baseline with sildenafil, while remaining low in the 
placebo group.  Resting Q showed temporary increases at altitude but was not affected by 
treatment.  Exercise Q was not effected by altitude or treatment.  A decrease in VO2 max was 
observed with altitude, but this decrease was significantly less in the sildenafil group, both on 
day 2 and on day 5 at altitude.  The intra-thoracic fluid index (a marker for pulmonary edema) 
increased with altitude in both groups but then decreased significantly after sildenafil 
administration.  The difference between alveolar and arterial oxygenation (PA-PaO2) at altitude 
was significantly greater in the placebo group than in the sildenafil group both at rest and during 
exercise.  Finally, in the sildenafil group, blood levels of cGMP were significantly increased at 
altitude compared to placebo.13 
 One subject in the placebo group experienced remarkably low SpO2 at altitude and was 
given supplemental O2 at night, but not in chronological proximity to any physiologic testing.  
He was not excluded from the study, but the authors state that there was no effect on the overall 
results if his data is excluded.13 
 Conclusions— The authors concluded that the main effect of sildenafil in this study was 
the reduction in hypoxia-induced pulmonary hypertension along with an improvement in 
peripheral oxygenation.  They also concluded that this was due to sildenafil’s effect on the 
pulmonary vasculature rather than on cardiac function.  This was based on a number of 
observations: both PAP and PAT decreased, which supports a decline in pulmonary 
vasoconstrictor response16; there was an increase in cGMP, which has well-documented 
pulmonary vasodilatory effects; aside from a mild decrease in HR, there was no effect on cardiac 
parameters, specifically cardiac output.  The effect on HR may be an indirect result of improved 
oxygenation or a direct effect of increased cGMP.13,17   
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The authors also noted that the effects of sildenafil on pulmonary hemodynamics were 
more pronounced later into the treatment phase when plasma levels of sildenafil were highest.  
Despite the short half-life (4 hours), it appears that continuous dosing over 5-6 days results in an 
increase in circulating drug levels, sufficient to increase its effectiveness.13 
Improved peripheral oxygenation and a decrease in the difference between alveolar and 
arterial oxygenation suggests an improvement in the ventilation-perfusion ratio, which the 
authors see as a likely result of decreased PAP and overall pulmonary edema as evidenced by the 
decrease in the intra-thoracic fluid index.  This has positive implications for the potential use in 
the prevention of HAPE, however no definitive conclusions regarding this application can be 
made from this particular study as none of the participants experienced symptoms of HAPE.13 
This study did show a small but significant improvement in VO2 max with sildenafil 
suggesting it can limit the negative effects of hypoxia on exercise tolerance.  There was no effect 
on AMS symptoms, but this may be masked by the side effects of sildenafil which similarly 
include headache as the main symptom.  Overall sildenafil had few adverse effects and did 
demonstrate significant improvement in a number of important measurements, so sildenafil 
presents a potential treatment modality for HAPE, however more research is needed to compare 
its efficacy to the currently accepted treatments.13 
DISCUSSION 
 Inadequate nitric-oxide levels in the presence of hypoxia have been shown to decrease 
the amount of available cGMP, which leads to cause exaggerated pulmonary vasoconstriction 
and pulmonary hypertension.4  This is a major risk factor for developing high altitude pulmonary 
edema (HAPE).  The enzyme PDE-5 decreases cGMP, therefore PDE-5 inhibitors, such as 
Viagra (sildenafil), have been shown to increase cGMP and attenuate hypoxia-induced 
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pulmonary vasoconstriction.  Does sildenafil maintain these effects during hypoxic exercise and 
will it improve athletic performance at altitude? 
 Pulmonary artery pressure (PAP) is one of the diagnostic criteria for pulmonary 
hypertension and a marker for HAPE. Numerous studies have already shown that sildenafil 
attenuates the increase in PAP during hypoxia, and the five studies considered in this review 
have shown that this is also true during hypoxic exercise.  Three of the studies11,12,13 measured 
PAP directly, and the other two studies9,10 used surrogate cardiac parameters which indirectly 
support a decrease in PAP.  The Lalande et al study,9 observed a decrease in RSVP, which 
correlates to a reduction in PAP as seen in other studies.11,12,13  However, the changes in RVSP 
do not necessarily reflect a change in PAP as other factors such as systemic BP and preload may 
influence this measurement.  Although none of the studies directly examined sildenafil’s effect 
on the occurrence of HAPE, the Richalet et al study13 did show a decrease in intra-thoracic fluid 
which has promising implications for pulmonary edema.  Despite these implications, none of the 
studies actually demonstrated a reduction in HAPE-related symptoms since none of the 
participants actually developed any symptoms that were severe enough to be reported.  A small 
number reported headaches and sleep disturbances as well as dyspepsia and facial flushing, but 
these were more likely symptoms of mild AMS or were an adverse reaction to sildenafil; they 
were not concerning for HAPE. 
 For the most part, the studies all showed that sildenafil improved peripheral oxygenation 
during hypoxic exercise, although one study9 showed no effect.  The Ghofrani et al study11 
showed that in chronic hypoxia, oxygenation improved in all participants but was not affected by 
sildenafil.  This suggests that after acclimatization has occurred, sildenafil provides little benefit 
for oxygenation and may be less useful in the setting of chronic hypoxia. 
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 In those studies which directly measured athletic performance10,11 significant 
improvements were observed by all in either finish time or maximum power output after taking 
sildenafil.  The Richalet study13 used VO2 max which has long been a surrogate marker for 
aerobic capacity and exercise tolerance, and they also found improvement with sildenafil.  
Furthermore, the Ghofrani study11 not only showed improvements in maximum power during 
acute hypoxia, but also after acclimatization during chronic hypoxia.  This suggests that 
sildenafil may have some effect on long-term pulmonary vascular remodeling which occurs 
during chronic hypoxia. 
 The most interesting, yet unexpected, finding was one reported in the Hsu et al study10 
which suggested the presence of two distinct subgroups with in the population: those who 
respond well to sildenafil and those who do not.  Overall they found that participants completed 
the time trial 15% faster after taking sildenafil, however sildenafil responders improved their 
performance by 39% (-4.4 ± 2.2 mins) while the non-responders showed no significant 
improvement (0.1 ± 0.2 mins).  There was a similar pattern associated with Q and SV.  
Interestingly, the sildenafil responders had better untreated SV at sea-level but also experienced 
the greatest decreases in SV during hypoxia.  This supports observations made by other studies 
showing that physically fit individuals are more likely to be negatively affected by hypoxia and 
are more prone to HAPE.18,19  It appears that sildenafil may be able to reverse these hypoxia-
related impairments, reduce the risk of HAPE, and help return exercise tolerance back towards 
baseline in those individuals who are predisposed to altitude sickness.  The problem with this 
finding is that it was made retrospectively and was not the original intent of the study.  Although 
there is significant improvement in the responders, there is no direct comparison between them 
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and the non-responders so one cannot be sure that there is any significant difference between the 
two groups initially.   
 This finding has implications for future studies as well as retrospective considerations for 
previous studies.  It has long been known that there is much variance in the individual 
susceptibility to HAPE, however now it seems that this susceptibility may be linked to one’s 
responsiveness to sildenafil.  The studies considered here only used healthy participants with no 
known history of HAPE or severe altitude sickness.  If a participant has not had much experience 
at high altitude, however, how is the individual to know if they are susceptible to altitude 
sickness?  In the future, it may be more appropriate to study sildenafil in the context of whether 
the subject is a responder or a non-responder.  It would also be interesting to see if 
responsiveness to sildenafil could be used to predict individual susceptibility to HAPE and 
altitude sickness. 
 The overall study quality, according to the GRADE criteria,8 was moderate.  All of the 
studies were double-blind randomized placebo-controlled studies, but there were a few 
limitations with them.  Two studies9,10 used surrogate measurements for PAP and both were 
conducted at sea-level where, although the subjects were breathing hypoxic air, the lack of 
hypobaric conditions may not have accurately reproduced the physiological changes that occur at 
altitude.  The Ricart et al study12 involved a small delay from the end of exercise to the 
beginning of the echocardiograph.  The authors insist that this delay was “insignificant” and that 
any impact would only serve to underestimate the effect.    One subject in the placebo group of 
the Richalet et al study13 experienced remarkably low SpO2 at altitude and was given 
supplemental O2 at night, but not in chronological proximity to any physiologic testing.  He was 
not excluded from the study, but the authors state that there was no effect on the overall results if 
[26] 
 
his data is excluded.  This still presents some concern as to the validity of that particular data set.  
The dose response observed with sildenafil in the Richalet et al study13 conflicts with the results 
of the Hsu et al study10 which showed no dose-response effect with sildenafil.  All of the studies 
used relatively small sample sizes and, with the exception of one,11 had issues with imprecise 
data and confidence interval overlap.  Larger study populations would fix this problem, however 
due to the logistically complex nature of many of these study procedures a larger study is 
probably not very practical.  . 
CONCLUSION  
 Sildenafil has been shown to ameliorate the pulmonary vascular effects of hypoxia, 
leading to better oxygenation and improved exercise tolerance without the potential for 
hypotension which is inherent with nifedipine.  These qualities may make sildenafil an attractive 
choice for performance-enhancement in individuals who are prone to high altitude sickness.  
However, we do not know if these effects are sufficient to significantly reduce the occurrence of 
HAPE, nor do we know if sildenafil is any more effective than nifedipine.  So while the role of 
sildenafil in preventing HAPE is promising, it is not conclusive.  Until more research is done 
sildenafil should only be recommended as an alternative for HAPE prophylaxis in individuals 
who do not tolerate nifedipine. 
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TABLE 1.  GRADE evidence profile: sildenafil as a high-altitude performance-enhancing drug 
M ethodology Inconsistency Indirectness Imprecision Publication bias Other Placebo Sildenafil
Lalande9 none none seriousb seriousc none none 15* 15* possiblye low
Hsu10 none none seriousb seriousc none none 10* 10* possiblye low
Richart12 seriousa none none none none none 14* 14* yes moderate
Richalet13 none none none none none none 6 6 yes high
Ghofrani11 none none none none none none 14* 14* yes high
Lalande9 none none none seriousc none none 15* 15* none moderate
Hsu10 none none none seriousc none none 10* 10* possiblye moderate
Richart12 none none none seriousc none none 14* 14* possiblye moderate
Richalet13 none none none none none none 6 6 yes high
Ghofrani11 none none none none none none 14* 14* yesd high
Hsu10 none none none none none none 10* 10* yes high
Richalet13 none none seriousb seriousc none none 6 6 yes low
Ghofrani11 none none none none none none 14* 14* yes high
b: surrogate endpoints used
c: significant confidence interval overlap
d: during exercise in acute hypoxia only
e: data tends to show some effect but lacks statisitcal significance or precision
f: very low (0), low (1), medium (2), high (3)
g: none (0), serious (-1), very serious (-2)
*: crossover study
not important
Prevents a rise in pulmonary artery pressure during hypoxia 
a: delay between exercise and echo
moderate
moderate
Prevents a decline in aerobic performance during hypoxia 
Prevents a decline in arterial oxygenation during hypoxia 
important
critical5 RCT
5 RCT
3 RCT moderate
Quality Assessment
ImportanceDowngrade Criteriag Number of Patients
QualityfDesignNo. o f Studies
Summary of Findings
Significant 
effect
Overall Qualityf
Study
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TABLE 2.  The Lake Louise Score for the Diagnosis of Acute Mountain Sickness 
 
